Research Paper Volume 13, Issue 20 pp 23579—23587
AHNAK suppresses ovarian cancer progression through the Wnt/β-catenin signaling pathway
Figure 4. AHNAK represses ovarian cancer progress by targeting the Wnt/β-catenin cascade. (A) Western blotting evaluation of the contents of Canonical Wnt cascade markers. The Western blotting image in the right panel exhibits that the Wnt inhibitor, DKK1, suppressed Wnt signaling of AHNAK-siRNA activated signal in OV119 and A2780 cells. (B) qRT-PCR assays of the contents of Canonical Wnt cascade markers. Data are presented as the mean ± SD for n=3, **p < 0.01.